AMGN · 10-Q · 2026Q2 · Full report

Geographic Market Commentary

AMGEN INC · 2026-08-05 · Importance 43 · Surprise 32

Demand growth was broad-based geographically, with second-quarter volume increasing 9% in the U.S. and 8% in ROW. For the first six months, ROW volume growth of 10% exceeded U.S. growth of 9%. Growth in both regions was led by Repatha, EVENITY, IMDELLTRA/IMDYLLTRA, UPLIZNA, PAVBLU and TEZSPIRE.

Key facts